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Intestinal parasites – helminths and protozoa – are cosmopolitan diseases which are most
prevalent in tropical regions. Patients with diagnoses of autoimmune rheumatic diseases
have, due to the underlying disease or its treatment, an increased risk of occurrence of
severe manifestations of intestinal parasites. Although the prevalence of these parasitic
infections is very high in our environment, not always is the rheumatologist attentive to
the  need for investigation and treatment of helminthiasis and protozooses before the use of
immunomodulatory, immunosuppressive therapies, and of biological drugs that are modi-
ﬁers  of the course of the disease. In this document, the Brazilian Society of Rheumatology
establishes general recommendations on the diagnosis and treatment of intestinal par-
asitic infections in Brazil in patients with autoimmune rheumatic diseases, highlightingrheumatoid arthritis, systemic lupus erythematosus and spondyloarthritis.
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Recomendac¸ões  da  Sociedade  Brasileira  de  Reumatologia  sobre
diagnóstico  e  tratamento  das  parasitoses  intestinais  em  pacientes  com
doenc¸as  reumáticas  autoimunes
Palavras-chave:
Enteropatias parasitárias
Diagnóstico
Terapêutica
Doenc¸as autoimunes
Doenc¸as reumáticas
r  e  s  u  m  o
As parasitoses intestinais – helmintíases e protozooses – são doenc¸as cosmopolitas com
maior prevalência em regiões tropicais. Pacientes com diagnóstico de doenc¸as reumáti-
cas  autoimunes apresentam, em func¸ão da própria doenc¸a de base ou de seu tratamento,
um maior risco de ocorrência de manifestac¸ões graves das parasitoses intestinais. Emb-
ora  a prevalência dessas parasitoses seja bastante elevada em nosso meio, nem sempre o
reumatologista está atento à necessidade de investigac¸ão e tratamento das helmintíases
e  protozooses antes do uso de terapias imunomoduladoras, imunossupressoras e dos
medicamentos biológicos modiﬁcadores do curso da doenc¸a. Neste documento, a Sociedade
Brasileira de Reumatologia estabelece recomendac¸ões gerais sobre o diagnóstico e trata-
mento das parasitoses intestinais no Brasil em pacientes com doenc¸as reumáticas
autoimunes, com destaque para a artrite reumatoide, o lúpus eritematoso sistêmico e as
espondiloartrites.
©  2014 Elsevier Editora Ltda. Todos os direitos reservados.
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ntestinal parasitic infections – helminthiasis and protozooses
 are cosmopolitan diseases with more  prevalence in tropi-
al regions. Intestinal parasites more  often found in humans
re: Ascaris lumbricoides, Trichuris trichiura and ancylosto-
ides: Necator americanus and Ancylostoma duodenale.  Among
he protozoa Entamoeba histolytica and Giardia intestinalis are
ighlighted.1
Patients with diagnoses of autoimmune rheumatic dis-
ases present, due to the underlying disease or its treatment,
n increased risk for severe manifestations of intestinal para-
ites. Although the prevalence of these parasites is very high
n our environment, not always is the rheumatologist aware
f the need for search and treatment of helminthiasis and
rotozooses before the use of immunomodulatory, immuno-
uppressive therapies, and immunobiological medications.
he non-recognition of these conditions can lead to serious
onsequences.
The Brazilian Society of Rheumatology (SBR) considered
hat it would be appropriate to make general recommenda-
ions on the diagnosis and treatment of intestinal parasitic
nfections in Brazil in patients with autoimmune rheumatic
iseases, highlighting rheumatoid arthritis (RA), systemic
upus erythematosus (SLE) and spondyloarthritis (SA).
bjective
o provide a document that represents the opinion of experts
ased on literature review of aspects related to the man-
gement of intestinal parasites in Brazil in patients with
utoimmune rheumatic diseases, identifying potential inter-
erence of this concurrence in the diagnosis and treatment of
utoimmune diseases.Method
The method for document preparation included a literature
review, performed by rheumatology experts who  are members
of the SBR. Specialists from the Committee on RA, Committee
on Endemic and Infectious Diseases, Committee on SLE, Com-
mittee on SA, and Committee of Epidemiology were invited,
among others. A bibliographic survey included publications in
MEDLINE, SciELO, PubMed and EMBASE databases up to Febru-
ary 2014. The recommendations were written and reassessed
by all participants during multiple rounds of questions and
corrections made via Internet.
This document is part of the SBR initiative to make rec-
ommendations on the diagnosis and treatment of endemic
and epidemic diseases in Brazil in patients with autoimmune
rheumatic diseases. In a previous document, recommen-
dations were given on Chagas disease, syphilis, dengue,
schistosomiasis, leishmaniasis and ﬁlariasis. The other
selected endemic diseases will be addressed in separate doc-
uments.
General  considerations  on  helminthiasis  and
protozooses
Helminthiasis and protozooses are diseases of spectral mani-
festation, ranging from asymptomatic cases to mild to severe
forms. In the most common presentations, symptoms are
nonspeciﬁc, such as anorexia, irritability, sleep disturbances,
nausea, vomiting, abdominal pain, and diarrhea. Severe cases
occur in patients with higher parasite load, and in immuno-
compromised and malnourished individuals.2 The onset or
exacerbation of malnutrition occurs through mucosal injury
(G. intestinalis, N. americanus, Strongyloides stercoralis,  coccidiosis),
change of biliary salts metabolism (G. intestinalis), competition
for food (A. lumbricoides), intestinal exsudation (G. intestinalis,
 o l . 2370  r e v b r a s r e u m a t
S. stercoralis,  N. americanus,  T. trichiura), bacterial proliferation
facilitation (E. histolytica)  and hemorrhages (N. americanus,  T.
trichiura).3
Parasitic diseases are the leading cause of morbidity and
mortality in the population with billions of people infected
worldwide. Of these, 300 million suffer from severe clini-
cal forms of parasitic infections, and 155,000 die each year
from these diseases.4 Many  infections occur throughout the
world, even in countries where there are infection prevention
measures, requiring considerable investment in public health
infrastructure.5
Ascariasis, trichuriasis and ancylostomides infections,
among other intestinal helminthiasis, are concentrated
amongst the poorest population and have high morbidity. It is
estimated that 20–30% of the population in America is infected
by A. lumbricoides, T. trichiura or ancylostomides and Schisto-
soma mansoni.6 These parasites affect respectively more  than
1.2 billion, 795 million, and 740 million of people in the world,
and can be considered the most prevalent human intestinal
infections.7
The reports made in the literature of prevalence of intesti-
nal parasites in Brazil are scarce and very speciﬁc. They are
usually described considering speciﬁc populations (school-
aged children, elderly or immunocompromised patients), only
reﬂecting the reality of small towns. Thus, you cannot have
a comprehensive picture of the prevalence of these parasitic
infections at national level.
The article by Basso and colleagues stands out. They have
studied the variation for 35 years (1969–2004) on enteral para-
sitic infections’ prevalence in school-aged people from the city
of Caxias do Sul, in the state of Rio Grande do Sul, evaluating
9787 parasitology fecal tests. These authors showed that the
general prevalence of intestinal parasitic infections decreased
from 89% to 37% and that there was a reduction in the preva-
lence of A. lumbricoides from 61% to 26% and of T. trichiura from
38% to 18%. For Giardia lamblia there was no signiﬁcant change.
The prevalence of Entamoeba coli increased from 29% to 46%.8
Barbosa and colleagues made an ecological study for geo-
helminths assessment analyzing secondary data from Zona
da Mata de Pernambuco (ZMP) covering 43 municipalities and
more  than 1100 million inhabitants. These authors demon-
strated that there was a higher spatial distribution of cases of
A. lumbricoides and T. trichiura in the south of ZMP,  and higher
incidence of tapeworms in the north and center of this region.
They concluded that although several studies revealed cases
of geo-helminths in the ZMP,  no effective preventive measure
to reduce these health risks has been implemented in this
endemic area.4
Giardiasis
Giardiasis is an intestinal parasitic disease caused by the ﬂag-
ellate, extracellular protozoan, parasite of the small intestine,
G. lamblia (synonyms: G. intestinalis,  Giardia duodenalis). It is an
important cause of world enteric diseases.9
In Brazil, the prevalence varies from 5.5% in children from
100 to 5 years in the city of São Paulo to 24% in school-aged
children in Caxias do Sul,8 achieving 32.8% in children below
7 years of age in day care centers in the city of São Paulo, and
75.2% in the rural areas of state of Pernambuco.11,12 0 1 5;5 5(4):368–380
The transmission of G. lamblia occurs through water; con-
sumption of vegetables and fruit contaminated by cysts; food
handlers; inter-human direct contact (fecal–oral), especially
in nursing homes, day care centers and psychiatric clinics.
Cysts may remain viable in a wet environment for a period
of 3 months and resist to usual chlorination of water. We  also
consider the transmission by arthropods through their stools
or re-regurgitation.13
Infections by G. lamblia may be presented in varied forms,
from asymptomatic cases to infections with acute diarrhea
followed by abdominal distension and pain. There may also
be chronic diarrhea followed by steatorrhea, weight loss, and
intestinal malabsorption in 30–50% of infected patients.1 Mal-
absorption of sugars, fats, and vitamins A, D, E, K, B12, folic
acid, iron, or zinc are also described.3 Skin manifestations,
allergies, and hives can also be described in patients with
giardiasis.14
Nitroimidazoles are drugs used to treat giardia-
sis and include metronidazole, secnidazole, tinidazole
and ornidazole.15 Other drugs such as benzimidazoles,
quinacrines, furazolidines, paromycin and nitazoxanide are
often used.16
Metronidazole is the most frequently used drug for the
treatment of human giardiasis; however, its use can cause
headache, dizziness, nausea, and metallic taste. A compar-
ative study of albendazole and metronidazole showed that
albendazole is an alternative drug to metronidazole for the
treatment of giardiasis.17
Nitazoxanide is a broad spectrum antiparasitic drug effec-
tive to treat helminths and protozoan.18 It is given orally; it
shows a good bioavailability and is an alternative drug for the
treatment of giardiasis in children younger than one year.19
Amoebiasis
Amoebiasis or amebic dysentery is classically deﬁned as an
infection (symptomatic or asymptomatic) caused by the pro-
tozoan E. histolytica.3 Among the species of amoebae found
in the gastrointestinal tract E. histolytica is the only one to
cause an invasive disease, designated intestinal or extrain-
testinal amoebiasis.20 In 1925, Brumpt suggested the existence
of another species of amoeba, Entamoeba dispar,  with asymp-
tomatic infection, but only during the 1990’s accumulated
evidence conﬁrmed the existence of two morphological iden-
tical amoebae, with E. dispar being non-pathogenic and the
other, the pathogenic form (E. histolytica).21 The two species
can be differentiated by molecular biology, biochemical or
immunological methods.22 The parasitological diagnosis of
intestinal amoebiasis is obtained by the search of parasites
in stool samples, with the search for cysts being performed in
consistent stools, and trophozoites in diarrheal stools. How-
ever, the technical inexperience, intermittent elimination of
the cyst of E. histolytica/E. dispar and no morphological dif-
ferentiation with other intestinal amoebae, and artifacts can
provide microscopic misdiagnosis.23
E. histolytica is widely distributed throughout the world.
Its prevalence is higher in countries of tropical and subtropi-
cal areas where the population is poor, with low sanitation.21
However, the increasing migration of people from developing
countries to developed countries favored the spread of the
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arasite throughout the world. There are large numbers of
eople infected in regions with cold climate such as Canada,
orth of the United States and Europe.24
The infection with E. histolytica is the cause of death in
pproximately 100,000 people per year, second only to malaria
n number of deaths by protozoa.25
Regarding national data on amoebiasis, its prevalence
anges from 3.4% in the population of the city of Salvador26
eaching 6.2% in students from the city of Bambuí (state of
inas Gerais)27 and reaching 20% also in school-aged children
n the city of Caxias do Sul (state of Rio Grande do Sul).8
The life cycle of the parasite has the following morpho-
ogical stages: trophozoites, precyst, metacyst and cysts. The
ransmission of amoebiasis is accomplished by the ingestion
f mature cysts that contaminate food and water through a
ecal–oral cycle. Less common forms of transmission include
ral and anal sex.1
E. histolytica is a parasite of the large intestine. It can remain
s a commensal parasite, or cause tissue invasion, leading
o intestinal or extraintestinal forms of the disease. Clini-
ally, amoebiasis can be asymptomatic, with most individuals
elonging to this group. The infection is detected by ﬁnding
ysts in the stool, a fact that makes the carriers asymptomatic
isseminators of the disease.28
The intestinal amoebiasis associated with E. histolytica is
haracterized by the presence of colon, sigmoid and rectum
lcers. Occasionally, the individuals develop amoebic colitis
ith profuse bloody diarrhea, fever, leukocytosis, frequent
bdominal pain with peritoneal signs, and extensive involve-
ent of the colon. Amoebic abscesses may occur, but the
ominant clinical picture in more  than 75% of the patients
ith fulminant amoebic colitis consists of intestinal perfo-
ation. Pregnant women, immunocompromised individuals,
atients with diabetes mellitus, alcoholics or those who are
n corticosteroids are at high risk for the fulminant disease.24
Regarding extraintestinal amoebiasis, the most common
orm consists of amoebic abscess due to the migration of
rophozoites through the superior mesenteric vein to the
iver.29,30 The invasion of the respiratory tract is usually sec-
ndary to liver abscess after being ruptured through the
iaphragm (7–20% of patients). However, brain abscess is rare
nd also occurs after rupture of hepatic abscess. The symp-
oms are abrupt and characterized by headache, vomiting,
eizures and behavioral changes.31
The drugs used for treating amoebiasis vary in effective-
ess and according to the site where parasites are often
ettled.32 Basically they fall into two classes: amoebicides
orking in the intestinal lumen and those working in the
issues.32
Nitroimidazoles comprise the main class of drugs, among
hich: secnidazol, metronidazole, tinidazole and ornidazole.
hey act in the intestinal lumen and tissues. Luminal amoe-
icides include: teclosan and etofamide.33
Metronidazole is the drug of choice for the treatment
f hepatic amoebiasis, followed by a luminal agent. How-
ver, patients may remain symptomatic with signiﬁcant
isk of rupture of the abscess into the peritoneum. In this
ase, for patients who have failed treatment of 5 or 7
ays, percutaneous aspiration may be necessary, although
his indication remains controversial.34,35 Reported cases 5;5 5(4):368–380 371
demonstrate the successful use of metronidazole for patients
with rheumatic disease.36 The standard treatment for amoe-
biasis with metronidazole is 500–750 mg  three times daily for
7–10 days for adults and 30–50 mg/kg/day for children for 5–10
days.32
Nitazoxanide was effective in the treatment of intestinal
and tissue amoebiasis.37 In Mexico, a comparative study of
nitazoxanide (200 mg  for 3 days) with mebendazole (200 mg
for 3 days) and/or quinfamide (100 mg  per 1 day) for sev-
eral intestinal parasitic infections showed 73.9% cure rates
for giardiasis and 80% for amoebiasis.38 In Egypt, a prospec-
tive, randomized, double-blind, placebo-controlled study was
performed to evaluate nitazoxanide efﬁcacy in treating diar-
rhea caused by G. lamblia and E. histolytica/E. dispar.  The results
showed a 81% overall cure of nitazoxanide compared to 40%
of the placebo group. For giardiasis, a cure of 91% versus 36%
of the placebo was observed. In cases of E. histolytica/E. dispar,
results showed 80% versus 48% of placebo and in mixed infec-
tions, 67% versus 25% of placebo.37 In Egypt, nitazoxanide was
also investigated in the treatment of intestinal and hepatic
amoebiasis in outpatients, in a double-blind, prospective, ran-
domized, placebo-controlled study. The results showed 94%
clinical and parasitological cure of the patients analyzed.39
Ascariasis
Ascariasis is an intestinal parasitic infection caused by the
helminth A. lumbricoides, the most common species of nema-
tode in humans, popularly known as “lombriga” (worm) in
Brazil.40
Data about the prevalence of ascariasis are very heteroge-
neous in Brazil, ranging from 4.4% in children of São Paulo
under ﬁve years of age,10 and 4.8% in students from the city of
Bambuí (state of Minas Gerais),27 to 47% of the students in the
city of Caxias do Sul (state of Rio Grande do Sul)8 and 48.8% of
individuals from zero to 86 years of age living in the state of
Minas Gerais.41
The symptomatology is directly related to the parasite
load. Infections by A. lumbricoides may be asymptomatic (3–4
worms), but the adult worms can cause predatory, toxic or
mechanical action (average of 30–40 worms). Massive infec-
tions (100 or more  worms) are also described, potentially
causing liver damage evolving to ﬁbrosis. Patients infected
with this helminth have a risk of progressing to malnutrition,
especially at childhood, due to a large consumption of protein,
vitamins, lipids and carbohydrates by the parasites.1
Other manifestations described include allergic reaction
to parasite antigens and lesions caused by the worm lar-
vae, pneumonic disease and intestinal obstruction. The main
characteristics of this obstruction are diarrhea followed by
constipation, abdominal pain, vomiting, history of elimination
of the parasite in the stool or by vomiting. The obstructive or
semiobstructive cases can cause death, especially in malnour-
ished children.1
AncylostomiasisAncylostomiasis is deﬁned as an intestinal parasitic disease
caused by nematodes of Ancylostomidae family: An. duode-
nale and N. americanus. In Brazil, the disease is popularly
 o l . 2
tion, larvae can be found anywhere, particularly in the sputum
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known as “amarelão” (skin yellowing), “opilac¸ão” or “Jeca
Tatu’s disease”.1
The ancylostomides have widespread geographic distri-
bution and high prevalence, being an infection that is more
common in rural areas.42 On this parasite group, the study
published by Mudenda and colleagues stands out, in which
risk maps were elaborated on a national scale (980 municipal-
ities) through the application of known biological information
on N. americanus using data on climate conditions appropriate
for this species of ancylostomiasis.43 The average preva-
lence of ancylostomiasis among the municipalities obtained
by the model was 5% (range = 0–70.2%; standard deviation
[SD] = 8.9%). These researchers also included data from 30
independent articles published between 1990 and 2010 by
several other authors in the study, in order to validate risk
prediction in the developed models. Such articles covered 16
of the 26 states of Brazil. The prevalence of ancylostomiasis in
these articles was calculated according to the model ranging
from 0% (city of São Paulo/state of São Paulo) to 80.2% (city of
São Lourenc¸o da Mata/state of Pernambuco), with an average
of 20.3% (SD = 22, 3%).43
Although the primary signal of ancylostomiasis is anemia,
its symptoms depend on the intensity of parasitism. The ancy-
lostomides’ eggs are eliminated in human feces and when
they ﬁnd a proper environment, with good oxygenation, high
humidity and high temperature, they evolve to the larval form.
These ﬁlarioid larvae penetrate the skin, conjunctiva, mucous
membranes, or can be swallowed. After penetrating the skin,
they reach the blood and lymph circulation and lodge in the
heart and lungs. The skin condition is manifested by an itching
dermatitis at the site of penetration of the larvae. Pulmonary
manifestations are nonspeciﬁc and there may be long- or
short-term cough, sputum and mild fever. Intestinal involve-
ment is accompanied by epigastric pain, nausea, vomiting and
diarrhea or constipation.1
Treatment for nematodes transmitted in soil such as
A. lumbricoides and ancylostomides include benzimidazoles,
broad-spectrum agents, especially albendazole, mebendazole
and thiabendazole. Mebendazole and albendazole are better
tolerated. Thiabendazol is clinically less used because of its
clinical toxicity, as it causes signiﬁcant nausea, vomiting and
anorexia at therapeutic doses.44
Benzimidazoles are selective agents for -tubulin of nema-
todes conferring a selective drug action to the parasite protein.
For the treatment of ascariasis and ancylostomiasis, ther-
apy regimens will vary depending on the drug of choice.45,46
For adults and children over 2 years of age with ascaria-
sis and ancylostomiasis, the treatment with albendazole is
accomplished with a single dose of 400 mg  orally and for
mebendazole 100 mg,  twice daily orally, for 3 days, or a single
dose of 500 mg  orally.47
Cure rates show to be varied according to the therapeu-
tic regimens. A single dose of albendazole and mebendazole
showed high cure rates for A. lumbricoides. In ancylostomides
infections, a single dose of albendazole was more  effective
than mebendazol.48–50
Nitazoxanide is a nitrothiazole derivative used for the
treatment of intestinal protozoa and helminths, including
A. lumbricoides and ancylostomides. A clinical trial was con-
ducted of nitazoxanide 200 mg  twice a day for 3 days, which 0 1 5;5 5(4):368–380
showed efﬁcacy of 89% in ascariasis compared to albendazole
single dose with 91% efﬁcacy.51 However, later, a controlled,
double-blind, randomized clinical trial was performed in poly-
parasited patients to evaluate the efﬁcacy of nitazoxanide
(twice daily for 3 days, 15 mg/kg/day for children and 500 mg
for adults), compared to other antiparasitic drugs (alben-
dazole, thiabendazole, praziquantel and secnidazole). The
cure rate observed was 32.4% for nitazoxanide and 38.7% for
conventional medication.52 The results showed that the effec-
tiveness pattern for both treatments was considered low in
comparison to studies performed to evaluate monoparasitism
treatment.
Strongyloidiasis
S. stercoralis is an intestinal nematode found all over the world
in moist soils contaminated with human feces.53,54
Although S. stercoralis infections occur almost all over the
world but the northern and southern end, estimates of its
prevalence are often little more  than suppositions. Schär et al.
published a systematic review of literature including 354 arti-
cles on the global distribution of the disease in 78 countries.55
These authors showed that, although the disease is endemic
in many  regions of the world, their infection rates in many
countries in these regions are very heterogeneous. In Africa
they range from 0.1% in Central Africa Republic to 91.8% in
Gabon, while in South and Central America they range from
1% in Haiti to 75.3% in Peru. In Southeast Asia they range from
0.02% in Vietnam to 23.7% in Thailand. It is believed that S.
stercoralis infections are underreported.55
With regard to prevalence data on S. stercoralis in Brazil,
we highlight the review published by Paula and Costa-Cruz.56
These authors showed that, when parasitological methods are
used, the prevalence of strongyloidiasis was 5.5%, characteriz-
ing the country as hyperendemic for this parasitic infection.56
They stressed that the occurrence increases with age, with
12.1% for persons aged over 60 years, suggesting that it is
an epidemiological condition of concern for the elderly. From
seroepidemiological studies of the general population, the
average positivity ranged from 21.7% (immunoﬂuorescence)
to 29.2% (enzyme-linked immunosorbent assay – ELISA).56
S. stercoralis has two types of larvae, the rhabditiform and
the ﬁlariform. In autoinfection rhabditiform larva becomes
an infective ﬁlariform, and can penetrate both the intesti-
nal mucosa (internal autoinfection) and perianal area skin
(external autoinfection). In both cases, the ﬁlariform larvae
can follow the previously described route, being successively
carried to the lungs, respiratory tract, pharynx and small
intestine, where they mature into adult worms or can spread
throughout the body.57
Depending on the host immune response, autoinfection
and/or hyperinfection may occur. The autoinfection allows the
parasite to survive for a long time in the usually asymptomatic
human host. Hyperinfection consists of an intense autoinfec-
tion process, a stage in which larvae can be found in fresh
feces. In the disseminated infection resulting from hyperinfec-and skin.
Clinically, larval dermatitis in the feet, hands, buttocks,
or in the anogenital region may occur. Other manifesta-
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ions include abdominal or epigastric pain, anorexia, nausea,
omiting, weight loss, secretory diarrhea or steatorrhea, and
rotein–calorie malnutrition. In many  patients there may
e urticarial rash. Disseminated strongyloidiasis occurs in
mmunocompromised patients (transplanted, malnourished,
lderly individuals, patients on prolonged use of corticosteroid
herapy, leukemia, lymphoma and acquired immunodeﬁ-
iency syndrome (aids)), and is characterized as a severe
ondition with high mortality.54
The treatment of strongyloidiasis includes drugs of the
enzimidazoles group – albendazole and thiabendazole – and
vermectin.58,59 Ivermectin is associated with increased elimi-
ation of S. stercoralis larvae compared to albendazole, and has
ewer side effects than thiabendazole.60
Ivermectin (single dose, 200 mg/kg) and thiabendazole
25 mg/kg twice a day for 2 days) safety and efﬁcacy were eval-
ated for cure of strongyloidiasis by a randomized clinical
rial. Thiabendazole was more  effective (95%) than ivermectin
86%). Ivermectin is considered the treatment of choice as it
s better tolerated than thiabendazole, and provides higher
fﬁcacy than albendazole.61,62
In the case of disseminated strongyloidiasis and when oral
dministration of ivermectin is not possible, studies report
arenteral use. However issues related to posology and safety
ave yet to be conclusive.60,63,64
ntestinal  parasitic  infections  in  patients  with
utoimmune  rheumatic  diseases
ystemic  lupus  erythematosus
ost of the literature data relating to the occurrence of
ntestinal parasites in SLE patients include case reports from
everal countries, mainly related to S. stercoralis and Enta-
oeba. In general, these patients generally progress to severe,
r even fulminant cases, especially in patients with active
isease, with glomerular renal impairment, chronic corticos-
eroid users and/or those who used high doses of these drugs
≥0.5 mg/kg/day of prednisone).
The occurrence of severe opportunistic infections by S. ster-
oralis in a patient with SLE was described by Wachter et al.65
t the time the patient developed fever and coma, with exam-
nation consistent with vasculitis, the therapy with high doses
f corticosteroids failed. Larvae of S. stercoralis were found in
eces and sputum. Treated with thiabendazole, the patient
ecovered quickly.
In 1988, Livneh and colleagues described a case of hyperin-
ection syndrome by S. stercoralis simulating ﬂare in a patient
ith SLE.66 Years later, Hayden and Atlas reported, in the
nited States, a case of strongyloidiasis simulating inﬂamma-
ory bowel disease.67 Later, in 2006, Yoshida et al. described
ecurrent episodes of paralytic ileus due to S. stercoralis in a
atient with SLE and a host for human T-cell lymphotropic
irus type I (HTLV-I) on steroid therapy.68 The patient came
rom an endemic area and had a history of strongyloidia-
is eight years before. After treatment with ivermectin she
mproved and showed no recurrence.
Deaths due to S. stercoralis presence have been described by
everal authors. In Japan, Setoyama and colleagues reported 5;5 5(4):368–380 373
a case of death due to disseminated strongyloidiasis in
patients with SLE and alveolar hemorrhage induced by ﬁlar-
iform larva.69 In another report, a young patient with SLE,
glomerulonephritis and chronic use of corticosteroids from
the endemic rural area of Bosnia and Herzegovina had severe
gastric and pulmonary symptoms, associated with weight loss
of 13 kg in 3 months. Search for larvae in the feces, sputum and
urine conﬁrmed the presence of nematodes, also observed in
the histopathological examination of the intestinal mucosa.70
In Lima (Peru), Mora,  Segami and Hidalgo reported two
cases of SLE and anti-phospholipid syndrome (APS) that devel-
oped hyperinfection by S. stercoralis – a woman of 34 years
and a man  of 37, with one of them progressing to death.71
Both had glomerulonephritis and were treated with immuno-
suppressants in high doses for initial suspicion of necrotizing
vasculitis. The ﬁrst one had a stroke, being hospitalized many
times due to infection, vomiting and diarrhea with suspected
vasculitis of the digestive tract. Gastric biopsy revealed S.
stercoralis and the patient improved after the use of iver-
mectin. In the second case, the patient developed recurrent
thrombosis and digital necrosis. He progressed with alveolar
hemorrhage and respiratory failure, septic shock and death.
The bronchoalveolar lavage studies conﬁrmed the presence of
Strongyloides larvae. The authors concluded by suggesting that
hyperinfection with S. stercoralis may exacerbate cases of SLE
and APS, predisposing to infection by Gram-negative bacteria,
sepsis and death. A similar case of SLE and APS complicated by
disseminated strongyloidiasis was again described in 2010.72
In 2013, Wang and colleagues evaluated the reports of 106
cases of strongyloidiasis that occurred in China between 1973
and 2012 in subjects aged 5–88 years. Among the 106 cases of
strongyloidiasis found, 68% had other diseases or were taking
immunosuppressive drugs. Five patients (5.3%) had a diagno-
sis of SLE.73
Caramaschi et al. described a case of SLE complicated
by strongyloidiasis in which the patient received ivermectin
(18 mg/day for 2 consecutive days, two cycles in 2 weeks),
with remission of diarrhea, polyarthritis and normalization of
eosinophilia.74 It is recommended that before starting treat-
ment with corticosteroids in patients with SLE, the presence
of S. stercoralis,  and subsequent treatment with ivermectin, is
evaluated.
The cases described in the literature about the association
between SLE and amebiasis reﬂect the occurrence of severe
opportunistic infections, central nervous system involvement,
and fulmimant cases of colitis, often simulating severe sys-
temic disease activity, and culminating in patients’ death
(Table 1).
Rheumatoid  arthritis
In a similar manner to that shown in relation to SLE, studies
that relate the occurrence of intestinal parasites in patients
with RA are scarce, basically restricted to case reports and case
series, mainly of strongyloidiasis. We highlight two review
studies published recently. In the ﬁrst, a systematic review
of case reports on the hyperinfection syndrome and dis-
seminated strongyloidiasis published by Buonfrate et al.,83
studies published between 1991 and 2011 are researched. The
study included 231 full articles related to 244 patients. A high
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Table 1 – Reports of severe cases of amoebiasis – patients with systemic lupus erythematosus.
Authors/year Therapy used Event Etiological agent/isolated material Manifestations/evolution
Grunnet al.
(1981)75
SLE/
immunosuppressor
Fulminant menin-
goencephalitis
Acanthamoeba castellanii
(Trophozoites in the lung)
Possible primary focus in the
lung/death
Tai and Fong
(1997)76
SLE/
immunosuppressor
Fulminant colitis Entamoeba histolytica (Trophozoites
in intestinal mucosa)
Intestinal amoebiasis
complicated by
Salmonella/Sepsis and death
Okusawa et al.
(1998)77
SLE/
immunosuppressor
Granulomatous
encephalitis
Acanthamoeba encephalitidis
(Trophozoites in the lung)
Possible primary focus in the
lung/death
Shrestha et al.
(2003)78
SLE/
immunosuppressor
Meningoencephalitis Entamoeba histolytica
(Trophozoites from the species
Naegleria fowleri in the
cerebrospinal ﬂuid)
Death
Shirwadkar et al.
(2006)79
SLE/
immunosuppressor
Encephalitis Acanthamoeba mitochondrial
(Neuropathological exam)
Death
Lange et al.
(2008)80
Juvenile SLE/
immunosuppressor
Meningoencephalitis
with central nervous
system vasculitis
Acanthamoeba meningoencephalitis
(Neuropathological exam)
Multiple hemorrhagic focci in
leptomeninges/death
Castillo et al.
(2012)81
Juvenile SLE/
immunosuppressor
Meningoencephalitis Acanthamoeba meningoencephalitis
(Trophozoites in cerebral biopsy)
Behavioral change, coma and
death
Lee et al. (2012)36 SLE/
immunosuppressor
Amoebic colitis Entamoeba histolytica (Trophozoites
in resected colon)
Multiple intestinal
perforations, respiratory
failure. Improvement with
antiparasitic therapy
Alkhunaizi et al.
(2013)82
SLE/
immunobiologicals
(Rituximabe)
Meningoencephalitis Acanthamoeba encephalitidis Behavioral change, headache.
It improves with treatment.SLE – systemic lupus erythematosus.
percentage of these patients (67% or 164/244) were on use
of corticosteroids, but only 4 (2.4%) had a diagnosis of RA.
In another review, Wang et al. reviewed the reports of 106
cases of strongyloidiasis (5–88 years old) occurring in China
between 1973 and 2012.73 Of these, 72 patients (68%) also had
other diseases or were taking immunosuppressive drugs, and
only 7 (9.7%) were patients diagnosed with RA. Besides these
two reviews, we  found some case reports. Later, in Table 2,
we present the most serious cases recently reported in the
literature.
There were no RA case reports with infections with other
parasitic diseases, including the last BiobadaBrasil report.89Spondyloarthritis
Similarly to what has been reported for SLE and RA, there
is a shortage of epidemiological studies about concomitant
Table 2 – Reports of severe cases of strongyloidiasis – patients w
Authors/year Event 
Koh et al. (2004)84 Pneumonia Me
Boatright and Wang (2005)85 Abdominal pain and
diarrhea
Eta
Miguel-Fraile et al. (2006)86 Diarrhea, vomiting and
malaise
Me
pa
Das et al. (2007)87 Diarrhea and anorexia Pre
Altintop et al. (2010)88 Weakness, dyspepsy,
dyspnea and cough
MeSA and intestinal parasitic infections. The articles are usually
case reports and, in most cases, show the role of para-
sites as triggers of reactive arthritis. Thus, it is believed that
cases of strongyloidiasis, ascariasis, giardiasis and amebia-
sis can present with oligoarthritis and must be appropriately
treated.90,91 Moreover, patients with SA, such as ankylosing
spondylitis, and psoriatic arthritis, may exhibit asymptomatic
parasitic infections and, when receiving immunosuppressive
therapy, they become susceptible to developing serious infec-
tious conditions.92
Diagnosis  of  intestinal  parasitic  infections  in
patients  with  autoimmune  rheumatic  diseasesThe diagnosis of an opportunistic infection by intestinal para-
sites in patients with autoimmune diseases is often hampered
by the low level of suspicion, lack of eosinophilia and speciﬁc
ith rheumatoid arthritis.
Drugs used Manifestations/evolution
totrexate and prednisolone Lung hemorrhage/death
nercept and prednisone Latent abdominal infection
Resolution after treatment
totrexate, prednisone and
racetamol
Gastritis due to parasite/
Resolution after treatment
dnisone Duodenitis due to parasite
Resolution after treatment
totrexate and deﬂazacort Gastritis and duodenitis
due to parasite
Resolution after treatment
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Table 3 – Characteristics and clinical picture of parasitic infections.
Parasitic
infection
Etiological agent Transmission Characteristics Clinical picture
Giardiasis Giardia lamblia Cysts ingestion, orally Monoxenic cycle; parasite of the
small intestine; absence of a
pulmonary cycle; no tissue
invasion of trophozoites;
waterborne disease and
responsible for diarrhea outbreaks;
zoonosis; important cause of
diarrhea in children.
Asymptomatic or symptomatic
forms; acute or chronic diarrhea;
steatorrhea; abdominal
discomfort; nausea; weight loss;
vomiting; ﬂatulence; malaise.
Amoebiasis Entamoeba
histolytica
Cysts ingestion, orally Monoxenic cycle; parasite of the
large intestine; likelihood of tissue
invasion; extraintestinal
amebiasis; absence of a pulmonary
cycle; asymptomatic patients are
an important source of infection;
food handlers play an important
role in the transmission;
morphologically similar to
Entamoeba dispar.
Asymptomatic or symptomatic
forms; dysenteric and
non-dysenteric colitis; mucous
and bloody stools; amebic
appendicitis; extraintestinal
amebiasis; hepatic abscesses;
fever; hepatomegaly.
Ascarisis Ascaris
lumbricoides
Eggs ingestion, orally Monoxenic cycle; infects uniquely
humans; parasite of the small
intestine; pulmonary cycle in the
larval stage, erratic parasite.
Asymptomatic or symptomatic
forms which are determined by
the number of parasites;
abdominal symptoms, pulmonary
symptoms; elimination of adult
worms; intestinal occlusion or
obstruction; Loefﬂer’s syndrome.
Ancylostomiasis Ancylostoma
duodenale/Necator
americanus
Infective larvae
penetration in the skin
or mucosas
Monoxenic cycle; parasite of the
small intestine; pulmonary cycle;
parasite blood spoliation that
causes anemia in the host
proportional to the parasite load
Abdominal and pulmonary
symptoms; transient cutaneous
manifestations; iron deﬁciency
anemia; hypoalbuminemia; fecal
occult blood; Loefﬂer’s syndrome.
Strongyloidiasis Strongyloides
stercoralis
Infective larvae
penetration in the skin
or mucosas, possible
autoinfection
Monoxenic cycle; parasite of the
small intestine in which the
female parasite lodges in the
intestinal villi; pulmonary cycle;
eggs hatch still within the
intestine; hyperinfection and
dis
im
Asymptomatic or symptomatic
forms, skin, lung and intestinal
symptoms; epigastric pain is a
frequent report; Loefﬂer’s
syndrome; cases of hyperinfection
and disseminated forms in
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tigns of infection – all of which can be associated with the
se of immunosuppressants, in particular the use of cortico-
teroids. Signs and symptoms of spread may be as fast as 20
ays after initiation of steroid therapy, or late – appearing years
fter the start of treatment. In addition, eosinophilia is often
bsent in disseminated infections and in patients receiving
orticosteroids. Intestinal parasites can mimic  the diseases
nd the use of corticosteroids may be associated with normal
erum levels of eosinophils, delaying diagnosis and facilitating
he progression to serious and fatal forms.93
mmunosuppression  interference  in  the
rogression  of  intestinal  parasitic  infections  in
atients  with  autoimmune  rheumatic  diseases
lthough in most patients E. histolytica occurs asymp-
omatically in immunocompromised patients receiving
hemotherapy or corticosteroid therapy, or in transplant
atients, there is high risk of fulminant amoebic coli-
is development. The mechanism by which amoebiasisseminated forms described in
munocompromised patients.
immunocompromised patients.
is exacerbated in cases of immunosuppression remains
undetermined.94–97
Corticosteroids are widely used in SLE patients and have
been associated with hyperinfection with S. stercoralis in
animal and human models. Some mechanisms have been
proposed. One of them consists of the hypothesis that
corticosteroids stimulate the virulence of the nematode
through activation of its receptors. The other states impaired
immunity mediated by T cells, facilitating the spread of S.
stercoralis.98
Another related theory is based on the assumption that
corticosteroids could reduce local inﬂammation. That would
undermine intestine ability to contain parasites. With the
increase in the number of larvae completing the autoinfection
cycle, large numbers of larvae could reach the systemic circu-
lation, producing hyperinfection and even sepsis or meningitis
with high morbidity and mortality in immunocompromised
99patients.
Disseminated infections by S. stercoralis have been reported
in people with a wide variety of immunological changes:
hematopoietic malignancies or connective tissue diseases
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Table 4 – Recommendations regarding management of parasitic infections in patients with autoimmune rheumatic
diseases.
Parasitic
infections
Parasitological tests Complementary
diagnostic tests
Treatment options Prophylaxis Recommendations
for patients with
autoimmune
rheumatic diseases
Giardiasis Spontaneous
sedimentation;
Ritchie’s
method/cysts and
trophozoites search
Intermittent
elimination of
parasitic forms may
require the
collection of stools
every seven days;
evaluation of
duodenal content
for search of
trophozoites; search
for antigen in stools
Metronidazole 250 mg,
(orally) PO, bid, for 3 to
5 days; secnidazole 2 g,
PO, single dose;
albendazole 400 mg,
PO, once a day for 5
days; nitazoxanide
500 mg, PO, bid for 3 to
7 days.
Proper cleaning of
fruits and
vegetables; use of
ﬁltered or boiled
water; control of
mechanical vectors;
health education.
Prophylaxis before the
onset of
immunomodulatory,
immunosuppressive or
immunobiological drugs
with secnidazole, 2 g, orally,
single dose. Repeat
annually if patient’s
immunosuppression
persists and he/she lives in
endemic areas
Amoebiasis Spontaneous
sedimentation;
Ritchie’s
method/search for
cysts and
trophozoites.
Serological methods;
search for antigen in
stools;
ultrasonography in
cases of amebic
abscess
Metronidazole
500–750 mg, PO, bid for
7–10 days; secnidazole
2 g, PO, single dose;
tinidazole 2 g, PO, for 2
days; nitazoxanide
500 mg, PO, bid for 3 to
7 days.
Proper cleaning of
fruits and
vegetables; use of
ﬁltered or boiled
water; control of
mechanical vectors;
health education
Prophylaxis before the
onset of
immunomodulatory,
immunosuppressive or
immunobiological drugs
with secnidazole, 2 g oral,
single dose. Repeat
annually if patient’s
immunosuppression
persists and he/she lives in
endemic areas
Ascariasis Spontaneous
sedimentation;
Kato-katz
method/eggs search
Elimination of adult
worm; eosinophilia
Albendazol 400 mg, PO,
single dose;
mebendazole 100 mg,
PO, bid, for 3 days or
500 mg, VO, single dose;
Nitazoxanide 500 mg,
PO, bid for 3 to 7 days.
Health education;
sanitation; hands
and food washing.
Prophylaxis before the
onset of
immunomodulatory,
immunosuppressive or
immunobiological drugs,
with albendazole, 400 mg
orally, a single dose. Repeat
annually if the patient’s
immunosuppression
persists and he/she lives in
endemic areas
Ancylostomiasis Spontaneous
sedimentation;
Willis method/eggs
search
Investigate the
presence of anemia
Albendazole 400 mg,
PO, single dose;
mebendazole 100 mg,
PO, bid, for 3 days or
500 mg, PO, single dose;
nitazoxanide 500 mg,
PO, bid for 3 to 7 days
Health education;
sanitation; hands
and food washing;
use of shoes.
Prophylaxis before the
onset of
immunomodulatory,
immunosuppressive or
immunobiological drugs,
with albendazole, 400 mg
orally, a single dose. Repeat
annually if the patient’s
immunosuppression
persists and he/she lives in
endemic areas
Strongyloidiasis Baermann-Moraes
method; Rugai
method, Mattos and
Brisola- use fresh
stools/Search for
larvae
Cases of
hyperinfection;
larvae are found in
body ﬂuids.
Ivermectin 200 g/kg,
PO, 1 to 2 days;
albendazole
400 mg/day PO, during 3
days; tiabendazole
25 mg/kg, PO, bid, for 2
days.
Health education;
sanitation; hands
and food washing;
use of shoes.
Prophylaxis before the
onset of
immunomodulatory,
immunosuppressive or
immunobiological drugs,
with ivermectin
200 g/kg/day, orally, for 2
consecutive days, repeated
within 2 weeks. Repeat
prophylaxis each 6 months,
if immunomodulation or
immunosuppression
persists, if patient lives
permanently in endemic
area
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reated with immunosuppressive drugs, and hosts with
ongenital or acquired hypogammaglobulinemias. Patients
eing treated with corticosteroids, transplanted, with chronic
enal insufﬁciency, diabetes mellitus, chronic obstructive
ulmonary disease, asthma, chronic skin diseases, chronic
nfections (leprosy and tuberculosis), neoplasias (lymphoma,
eukemia and solid tumors), chronic alcoholism, human
mmunodeﬁciency virus syndrome and achlorhydria are at
igh risk for strongyloidiasis.53,100
The occurrence of hyperinfection with S. stercoralis is
ssociated with the use of corticosteroids at high, moder-
te or low doses, and the local injectable administration
f high levels of adrenocorticotropic hormones (endoge-
ous or pharmacologically administered). In addition to the
bove mentioned diseases, rheumatologic diseases associated
ith altered innate immunity are described in associa-
ion with secondary spread of S. stercoralis:  SLE, RA and
olymyositis.54
Other commonly used immunosuppressive drugs for
utoimmune rheumatic diseases have been associated with
he occurrence of hyperinfection with S. stercoralis,  such as
yclophosphamide, azathioprine, and methotrexate. However,
n all cases the patients were concomitantly on corticoste-
oids. Thus, it becomes difﬁcult to relate the occurrence of
ny other hyperinfection to any of those drugs.54,100
Both patients with SLE and those with RA and SA present
igher risks than the general population to develop serious
nfections or infestations by parasites that are being car-
ied, even if asymptomatically. The risks increase when these
atients are on immunobiological drugs. We  highlight the let-
er published by Boatright and Wang,85 where they report the
ole of prednisone combination with the biologic drug etaner-
ept in the occurrence of a case of strongyloidiasis.
The mortality of patients with disseminated strongyloidi-
sis in RA is very high, between 87% and 100%. This is due to
he difﬁculty of making early diagnosis and high potential for
atal complications.88
Tumor necrosis factor (TNF ) plays an important role
n cell-cell communication in invasive infections. The
h2 immune response is important in controlling various
elminth infections, and can be modiﬁed by glucocorticoids
nd biological agents. The Th1/Th2 ratio in peripheral blood
an be increased by treatment with anti-TNF- antibodies.
hus, it is plausible that these drugs can alter the immune
esponse allowing indolent intestinal parasites to be clinically
anifested.85
revention  of  hyperinfection  with  parasites  in
atients  with  autoimmune  rheumatic  diseases
mong the published works on prevention of parasites’ hyper-
nfection, we  highlight the systematic revision published by
antiago and Leitão.101 These authors pointed out that the
ymptoms of hyperinfection strongyloids syndrome may not
e recognized early, simulating an exacerbation of underly-
ng rheumatic disease such as SLE, leading to a disastrous
ncrease in immunosuppressive dose. Thus, the importance
f conducting a routine investigation for intestinal parasites
ecomes evident in patients from endemic areas such as Brazil 5;5 5(4):368–380 377
before inducing immunosuppression, particularly in patients
refractory to standard therapy.
It is important to use appropriate methods to search for
parasites, trying to minimize false negative results. While
there is some evidence on the usefulness of serological tests
following chronic strongyloidiasis, as the performance of
these tests in immunocompromised patients was not well
established, it may not be safe to use them for therapeutic
decisions.
Regarding ascariasis and ancylostomiasis, guidelines for
the prescription of drugs used in emergency SLE recom-
mend the use of albendazole 400 mg  orally (PO), for 3 days
and metronidazole 400 mg,  PO, each 12 h, for 5 days before
administration of cyclosphosphamide, even with negative
parasitological stool test. In cases of positive tests, cyclophos-
phamide should only be used after the parasite treatment.102
Santiago and Leitão found no speciﬁc study for immuno-
compromised patients with diagnosis of rheumatic diseases.
However, based on experimental studies for other diseases
such as hematologic malignancies, they suggested that before
starting immunosuppressive treatments prophylaxis with
ivermectin be performed. Although a deﬁnitive prophylactic
regimen has not been set, the option of 200 g/kg/day for 2
consecutive days, repeated within two weeks, seems to be a
reasonable approximation. Such a regimen should be repeated
every 6 months in case immunosuppression in permanent
residents of endemic areas persists.101
Since biological therapies have become very important for
the treatment of some rheumatic diseases such as RA and
psoriatic arthritis it has been suggested that the recommen-
dation of strongyloidiasis prophylaxis should be extended to
this type of therapy in patients from the endemic areas of S.
stercoralis.103
Recommendations  on  the  diagnosis  and
treatment  of  intestinal  parasitic  infections  in
patients  with  autoimmune  rheumatic  diseases
Tables 3 and 4 respectively summarize the main features
of parasitic diseases discussed in this document and the
recommendations on the management of these conditions
in patients with autoimmune rheumatic diseases, based on
information available in literature and on authors’ experience.
Conclusions
There are no prospective studies relating the prevalence of
intestinal parasites in patients with autoimmune rheumatic
diseases from endemic areas. However, although a large num-
ber of severe cases is expected from these areas, only a few
cases in the literature include this subject and, in clinical
practice, such cases are rare.
Even considering the possible rarity of cases of serious
parasitic infections in patients with autoimmune rheumatic
diseases, their severity and even mortality can be very high,
warranting speciﬁc measures to address these cases.
SBR experts established, in this document, recommen-
dations for the management of the main parasites found
 o l . 2
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in Brazil, in patients with autoimmune rheumatic diseases,
based on the information available in the literature and the
authors’ experience.
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